雷递网 雷建平 1月10日先声再明医药股份有限公司(简称:“先声再明医药”)日前递交招股书,准备在港交所上市。9个月营收12.38亿亏损3亿先声再明医药是先声药业集团旗下专注于抗肿瘤创新药研发、生产和商业化的生物医药公司,打造高价值创新管线,已上市产品组合包含恩泽舒、科赛拉、恩维达、恩度、恩立妥5款创新药。先声再明医药称,与全球合作伙伴的协同创新,为临床提供更有效的治疗手段,让更多肿瘤患者再现生机...
Source Link雷递网 雷建平 1月10日先声再明医药股份有限公司(简称:“先声再明医药”)日前递交招股书,准备在港交所上市。9个月营收12.38亿亏损3亿先声再明医药是先声药业集团旗下专注于抗肿瘤创新药研发、生产和商业化的生物医药公司,打造高价值创新管线,已上市产品组合包含恩泽舒、科赛拉、恩维达、恩度、恩立妥5款创新药。先声再明医药称,与全球合作伙伴的协同创新,为临床提供更有效的治疗手段,让更多肿瘤患者再现生机...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.